<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article113</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/DAPA-HF" style="display:block; margin-bottom:10px;">DAPA-HF Original</a></li>
<h2><strong>DAPA-HF</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction".<br/>
<br/>
The New England Journal of Medicine. 2019.<br/>
<br/>
PubMed • Full text • PDF<br/>
<br/>
<h2><strong>Contents</strong></h2><br/>
<br/>
1 Clinical Question<br/>
2 Bottom Line<br/>
3 Major Points<br/>
4 Guidelines<br/>
5 Design<br/>
6 Population<br/>
6.1 Inclusion Criteria<br/>
6.2 Exclusion Criteria<br/>
6.3 Baseline Characteristics<br/>
7 Interventions<br/>
8 Outcomes<br/>
8.1 Primary Outcomes<br/>
8.2 Secondary Outcomes<br/>
8.3 Additional Analyses<br/>
9 Criticisms<br/>
10 Funding<br/>
11 Further Reading<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
Does dapagliflozin improve outcomes in patients with heart failure and a reduced ejection fraction regardless of the presence or absence of type 2 diabetes?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
Among patients with heart failure and reduced ejection fraction, the SGLT2 inhibitor dapagliflozin decreased the risk of worsening heart failure or death from cardiovascular causes and improved symptom scores, irrespective of diabetes status.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/><br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/><br/>
<br/>
<h2><strong>Design</strong></h2><br/>
Phase 3, multicenter, double-blind, placebo-controlled randomized trial<br/>
N=4744 patients with heart failure and reduced ejection fraction<br/>
Intervention: Dapagliflozin (10 mg daily) (n=2373)<br/>
Control: Placebo (n=2371)<br/>
Median follow-up: 18.2 months<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
Inclusion Criteria:<br/>
- ≥18 years old<br/>
- NYHA class II, III, IV heart failure<br/>
- Ejection fraction ≤40%<br/>
- Elevated NT-proBNP levels<br/>
<br/>
Exclusion Criteria:<br/>
- Recently treated with or intolerant to SGLT2 inhibitors<br/>
- Type 1 diabetes<br/>
- Symptoms of hypotension, systolic BP &lt;95 mm Hg<br/>
- eGFR &lt;30 ml/min/1.73 m²<br/>
<br/>
Baseline Characteristics<br/>
- Well balanced between groups<br/>
- 42% with type 2 diabetes at baseline<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
Patients were randomized to either dapagliflozin or placebo along with standard heart failure therapy.<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
Primary Outcomes:<br/>
- Composite of worsening heart failure (hospitalization or urgent visit resulting in IV therapy) or cardiovascular death significantly lower in the dapagliflozin group (16.3% vs. placebo 21.2%; HR, 0.74; P&lt;0.001)<br/>
<br/>
Secondary Outcomes:<br/>
- Improved symptoms based on the Kansas City Cardiomyopathy Questionnaire<br/>
- No difference in the composite renal outcome between groups<br/>
<br/>
Additional Analyses<br/>
- Benefit observed early after randomization<br/>
- Similar benefits in patients without diabetes<br/>
- Few patients discontinued due to adverse effects<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/>
- Specific inclusion and exclusion criteria may limit generalizability<br/>
- Underrepresentation of certain demographics (e.g., black patients, very elderly)<br/>
- Low baseline use of sacubitril–valsartan<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
Funded by AstraZeneca.<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
Additional literature relevant to this clinical trial can be found in the Supplementary Appendix provided at NEJM.org.
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
